AlphAIAlphAI — Financial news for AI agents
quiverquant.comOCT 302 min read$REGN

REGENERON PHARMACEUTICALS ($REGN) Releases Q3 2026 Earnings

Regeneron Pharmaceuticals ($REGN) reported Q3 2026 earnings of $20.07 per share, exceeding estimates by $3.59. Revenue was $5.12 billion, surpassing forecasts by $485.6 million. Insiders sold shares, while hedge funds had mixed activity. Analysts set a median price target of $730.0.

Original reporting
quiverquant.com
Published Oct 30, 2026, 11:01 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 30, 2026, 11:53 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
REGENERON PHARMACEUTICALS ($REGN) Releases Q3 2026 Earnings — source image
Source · quiverquant.com
Decision brief

The 30-second read

$REGNBullishHigh
01

Why it matters

The surprise earnings are likely to trigger short-term buying pressure, though recent insider selling may introduce caution.

02

Market read

Earnings beat for a large-cap biotech provides a clear trading catalyst.

03

What to watch

Insider sales activity could temper enthusiasm.

Relevance 9/10Novelty 9/10Timing: after-market close Friday

Background

Regeneron posted its quarterly results, beating consensus on both earnings per share and revenue.

Company-level read

Ticker impact

$REGNBullishHigh confidence
Context

Regeneron reported Q3 2026 earnings of $20.07 EPS and $5.12B revenue, both beating estimates.

Expected impact

likely upward as market prices in the beat

Evidence & confidence

Strong EPS and revenue surprise on a large-cap biotech typically drives buying interest.

Market effects

Sector

Positive earnings may lift biotech sector peers.

Regional

U.S. market sentiment for healthcare stocks improves.

Global

Limited to U.S. and global biotech investors.

Counterpoint

What could challenge this read

Some investors may worry about high valuation after the beat.

Key entities

  • Company
    Regeneron Pharmaceuticals

    Biotech firm reporting Q3 2026 earnings.

Read at source← All news

StoryRegeneron posts Q3 2026 earnings beat, driven by Dupixent and Sanofi collaboration

Also covered by

5 outlets

Related articles

OCT 30
$REGNHighAI 9/10

Regeneron (REGN) stock trades up, here is why

Regeneron (REGN) shares rose 11.5% after reporting Q3 2026 revenue of $5.1B, up 36%, and EPS of $20.07, up 70%. The company cited record sales for key drugs and expanded its alliance with Sanofi. REGN also announced pipeline milestones and updated trial data for Libtayo. The stock has gained 17.3% YTD, reaching a 52-week high of $910.25.

theglobeandmail.com2 min
OCT 30
$REGNHighAI 9/10

Regeneron Q3 Revenue Rises 36%; Pipeline Advances, FDA Catalysts Ahead; Stock Up

Regeneron reported Q3 2026 revenue of $5.116B, up 36% YoY, with GAAP net income rising 33% to $1.949B. Key products like Dupixent and EYLEA HD saw significant sales growth. The company expanded its Sanofi collaboration, receiving a $1B upfront payment. Regeneron also advanced its pipeline with FDA approvals and positive clinical trial results. The stock is up 11.46%.

rttnews.com3 min
OCT 30
$REGNMedAI 8/10

What Regeneron Pharmaceuticals (REGN) Said on Its Q3 Earnings Call

Regeneron (REGN) reported Q3 earnings, highlighting pipeline milestones. The company expects an FDA decision for cemdisiran in November and plans to present initial data for its CIDEB-targeting siRNA. It also reported positive results for ubamatamab in ovarian cancer. Sanofi collaboration revenue reached $2.7B, with a $1B upfront payment expected in Q4. Regeneron generated $2.9B in free cash flow and plans $3B in share repurchases for the year.

finance.yahoo.com3 min
OCT 30
$REGNMed

Regeneron (REGN) Q3 2026 Earnings Call Transcript

Regeneron reported Q3 2026 earnings, with total revenue up 36% and non-GAAP EPS up 70% YoY. Key drugs Dupixent, EYLEA HD, and Libtayo set sales records. Dupixent global sales reached $6.5B, EYLEA HD U.S. sales hit $700M, and Libtayo global sales were $550M. The company highlighted pipeline progress in neuromuscular, metabolic, and oncology areas, with potential blockbuster opportunities.

finance.yahoo.com6 min